Badger Meter, Inc. (BMI) is a Wisconsin-based provider of water management solutions, including water meters, flow measurement hardware, connectivity technology, and related software. On Tuesday, the stock fell 5.90%, trading around $146.75 compared with a prior-session close of $155.95. The decline reversed part of a sharp multi-session advance and followed a downgrade of the shares by a sell-side research firm, with markets also weighing the company's mixed third-quarter results released last week.
The most immediate catalyst for Tuesday's slide was a rating change. Northcoast Research downgraded BMI to Neutral from Buy, issuing the call without a new price target. Downgrades of this kind typically prompt near-term selling as some investors reduce positions and others pause before adding to holdings. The move comes against a backdrop of mixed analyst commentary on the name: while several firms raised price targets following earnings, at least one other research house recently moved to a more cautious stance. The conflicting signals contributed to a risk-off tone in the stock's trading on Tuesday.
The downgrade landed shortly after BMI reported third-quarter results on October 22. The company posted earnings per share of $1.24, narrowly topping the consensus estimate of $1.23, but revenue of approximately $230.3 million came in below the roughly $240.35 million analysts had expected. That combination — a modest earnings beat offset by a top-line miss — created a nuanced fundamental picture. Despite the revenue shortfall, shares rallied strongly in the days following the report, aided by upbeat margin commentary, software growth, a dividend increase, and ongoing share buybacks. Tuesday's decline therefore also reflects investors locking in gains after a roughly 20% run over the prior week, a classic "buy the rumor, sell the news" pattern as the initial enthusiasm cooled.
The pullback occurred on elevated trading activity relative to the stock's typical volume, consistent with a meaningful reassessment by institutional and retail participants. Even after Tuesday's decline, BMI remains above both its 50-day moving average and its 200-day moving average, suggesting that the longer-term uptrend has not yet been broken despite the day's weakness. The move was largely company-specific rather than driven by broad sector or index dynamics; the stock's reaction was tied to its own ratings and earnings news rather than a pronounced shift in the broader industrial or technology complex. Investors should view the move primarily through the lens of stock-specific catalysts.
Looking ahead, attention will focus on whether the revenue trajectory improves and whether the company's advanced metering infrastructure (AMI) and software initiatives can sustain margin expansion. Upcoming quarterly results and management commentary will be closely watched for signs of sales reacceleration, given the modest year-over-year revenue growth reported last quarter. Analyst expectations remain varied, with a spread of price targets reflecting differing views on valuation, which remains elevated by traditional metrics. Key risks include potential delays in awarded project ramps, competitive pressures in the water technology space, and the possibility of further rating changes. Traders will also monitor technical support levels to gauge whether Tuesday's decline marks a healthy consolidation or the start of a deeper correction.
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies that are currently performing strongly. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under present market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Traders looking for systematic, data-driven approaches may find value in exploring these tools as part of their research process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BMI saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned negative. In 62 of the 97 cases, the stock moved further down in the following days. The odds of a decline are at 64%.
The 10-day RSI Indicator for BMI moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 19 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.
The Moving Average Convergence Divergence Histogram (MACD) for BMI turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 29 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
BMI broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 70 cases where BMI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
BMI moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMI crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
The 50-day moving average for BMI moved above the 200-day moving average on November 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMI advanced for three days, in 182 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 130 of 211 cases where BMI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. BMI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 49 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.714) is normal, around the industry mean (1.448). P/E Ratio (36.786) is within average values for comparable stocks, (5.350). Projected Growth (PEG Ratio) (2.931) is also within normal values, averaging (5.470). Dividend Yield (0.011) settles around the average of (0.012) among similar stocks. P/S Ratio (4.255) is also within normal values, averaging (32.028).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of flow measurement and control products
Industry ElectronicEquipmentInstruments